NO301522B1 - Fremgangsmåte for fremstilling av farmasöytisk preparat omfattende kalsitonin for intranasal tilförsel - Google Patents
Fremgangsmåte for fremstilling av farmasöytisk preparat omfattende kalsitonin for intranasal tilförsel Download PDFInfo
- Publication number
- NO301522B1 NO301522B1 NO911395A NO911395A NO301522B1 NO 301522 B1 NO301522 B1 NO 301522B1 NO 911395 A NO911395 A NO 911395A NO 911395 A NO911395 A NO 911395A NO 301522 B1 NO301522 B1 NO 301522B1
- Authority
- NO
- Norway
- Prior art keywords
- calcitonin
- intranasal administration
- mixture
- pharmaceutical
- adjusted
- Prior art date
Links
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims description 25
- 102000055006 Calcitonin Human genes 0.000 title claims description 21
- 108060001064 Calcitonin Proteins 0.000 title claims description 21
- 229960004015 calcitonin Drugs 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 24
- 108010068072 salmon calcitonin Proteins 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 description 8
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1001—Piston pumps
- B05B11/1016—Piston pumps the outlet valve having a valve seat located downstream a movable valve element controlled by a pressure actuated controlling element
- B05B11/1018—Piston pumps the outlet valve having a valve seat located downstream a movable valve element controlled by a pressure actuated controlling element and the controlling element cooperating with means for opening or closing the inlet valve
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1042—Components or details
- B05B11/1043—Sealing or attachment arrangements between pump and container
- B05B11/1046—Sealing or attachment arrangements between pump and container the pump chamber being arranged substantially coaxially to the neck of the container
- B05B11/1047—Sealing or attachment arrangements between pump and container the pump chamber being arranged substantially coaxially to the neck of the container the pump being preassembled as an independent unit before being mounted on the container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/44—Valves specially adapted therefor; Regulating devices
- B65D83/52—Valves specially adapted therefor; Regulating devices for metering
- B65D83/54—Metering valves ; Metering valve assemblies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO962122A NO962122D0 (no) | 1988-10-11 | 1996-05-24 | Farmasöytiske blandinger omfattende kalsitonin for intranasal tilförsel, samt en sprayenhet for tilförsel derav |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8822257A IT1227174B (it) | 1988-10-11 | 1988-10-11 | Composizioni farmaceutiche a base di calcitonina, somministrabili per via intranasale. |
| IT8822548A IT1227472B (it) | 1988-11-08 | 1988-11-08 | Confezione spray per la somministrazione intranasale di calcitonina. |
| PCT/EP1989/001186 WO1990003796A1 (en) | 1988-10-11 | 1989-10-09 | Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO911395L NO911395L (no) | 1991-04-10 |
| NO911395D0 NO911395D0 (no) | 1991-04-10 |
| NO301522B1 true NO301522B1 (no) | 1997-11-10 |
Family
ID=26328146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO911395A NO301522B1 (no) | 1988-10-11 | 1991-04-10 | Fremgangsmåte for fremstilling av farmasöytisk preparat omfattende kalsitonin for intranasal tilförsel |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP0363876B1 (ko) |
| JP (2) | JPH0649658B2 (ko) |
| KR (1) | KR0152065B1 (ko) |
| AU (1) | AU632520B2 (ko) |
| BR (1) | BR8907708A (ko) |
| CA (1) | CA2000336C (ko) |
| DE (1) | DE68912341T2 (ko) |
| DK (1) | DK64291D0 (ko) |
| ES (1) | ES2053905T3 (ko) |
| FI (1) | FI95201C (ko) |
| GR (1) | GR3007420T3 (ko) |
| HU (1) | HU212495B (ko) |
| IE (1) | IE62327B1 (ko) |
| IL (2) | IL91856A0 (ko) |
| NO (1) | NO301522B1 (ko) |
| NZ (1) | NZ230965A (ko) |
| RO (1) | RO113301B1 (ko) |
| RU (1) | RU2097064C1 (ko) |
| WO (1) | WO1990003796A1 (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026825A (en) * | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
| ES2067624T3 (es) * | 1989-11-16 | 1995-04-01 | Ph & T S R L | Un procedimiento de preparacion de una composicion farmaceutica liquida para administracion nasal. |
| IT1242019B (it) * | 1990-11-20 | 1994-02-02 | Ripari Gero Ist Farm Biolog | Composizioni farmaceutiche acquose a base di calcitonina, da somministrarsi per via nasale. |
| IT1282374B1 (it) * | 1996-01-31 | 1998-03-20 | Therapicon Srl | Composizioni farmaceutiche parenterali a base di calcitonine sintetiche a ph controllato con basso indice di dolorosita' |
| DE19731472C2 (de) * | 1997-07-22 | 2000-05-25 | Gerhard Zellner | Nasenspray-Flüssigkeit |
| IT1294191B1 (it) * | 1997-09-05 | 1999-03-22 | Alfa Wassermann Spa | Composizioni farmaceutiche contenenti calcitonina in un dosatore spray per somministrazione intranasale. |
| SE9901658D0 (sv) * | 1999-05-06 | 1999-05-06 | Astra Ab | New formulation |
| US6644305B2 (en) | 2000-04-14 | 2003-11-11 | Trudell Medical International | Nasal inhaler |
| AU2002333785A1 (en) * | 2002-09-03 | 2004-03-29 | Pharmacure Health Care Ab | Nasal sprays |
| US9050433B2 (en) * | 2007-11-29 | 2015-06-09 | Glaxo Group Limited | Dispensing device |
| GB2464282A (en) * | 2008-10-08 | 2010-04-14 | Archimedes Dev Ltd | A device for administering a dose of opioid analgesic |
| US9731869B2 (en) | 2011-02-04 | 2017-08-15 | Archimedes Development Limited | Container |
| DE102011082420B4 (de) * | 2011-09-09 | 2021-02-04 | Aptar Radolfzell Gmbh | Flüssigkeitsspender und Austragskopf für einen Flüssigkeitsspender |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA758010B (en) * | 1975-11-14 | 1977-08-31 | Syntex Inc | Nasal spray adapter |
| CY1490A (en) * | 1982-02-01 | 1990-02-16 | Sandoz Ltd | Improvements in or relating to nasal pharmaceutical compositions |
| JPS5989619A (ja) * | 1982-10-05 | 1984-05-23 | サンド・アクチエンゲゼルシヤフト | カルシトニン組成物およびその用途 |
| FR2561565B1 (fr) * | 1984-03-23 | 1986-08-01 | Norlac Plastiques Sa | Couteau electrique destine notamment a l'ouverture des huitres |
| GB8407907D0 (en) * | 1984-03-27 | 1984-05-02 | Sandoz Ltd | Organic compounds |
| JPS61118325A (ja) * | 1984-11-12 | 1986-06-05 | Yamanouchi Pharmaceut Co Ltd | 塩基性および／または中性アミノ酸を含有するカルシトニン経鼻剤 |
| JPS61126034A (ja) * | 1984-11-26 | 1986-06-13 | Yamanouchi Pharmaceut Co Ltd | アルド−スを含有するカルシトニン経鼻剤 |
| JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| JPS6310735A (ja) * | 1986-07-02 | 1988-01-18 | Yamanouchi Pharmaceut Co Ltd | カルシトニン経鼻剤 |
| JPS6339822A (ja) * | 1986-08-04 | 1988-02-20 | Yamanouchi Pharmaceut Co Ltd | カルシトニン経鼻剤 |
-
1989
- 1989-10-02 IL IL91856A patent/IL91856A0/xx unknown
- 1989-10-09 ES ES89118734T patent/ES2053905T3/es not_active Expired - Lifetime
- 1989-10-09 RU SU4895203/14A patent/RU2097064C1/ru not_active IP Right Cessation
- 1989-10-09 EP EP89118734A patent/EP0363876B1/en not_active Expired - Lifetime
- 1989-10-09 WO PCT/EP1989/001186 patent/WO1990003796A1/en active IP Right Grant
- 1989-10-09 RO RO147309A patent/RO113301B1/ro unknown
- 1989-10-09 HU HU896876A patent/HU212495B/hu not_active IP Right Cessation
- 1989-10-09 IE IE325989A patent/IE62327B1/en not_active IP Right Cessation
- 1989-10-09 JP JP2500510A patent/JPH0649658B2/ja not_active Expired - Lifetime
- 1989-10-09 AU AU46225/89A patent/AU632520B2/en not_active Ceased
- 1989-10-09 BR BR898907708A patent/BR8907708A/pt not_active IP Right Cessation
- 1989-10-09 EP EP89912812A patent/EP0438531B1/en not_active Expired - Lifetime
- 1989-10-09 KR KR1019900701225A patent/KR0152065B1/ko not_active IP Right Cessation
- 1989-10-09 DE DE89912812T patent/DE68912341T2/de not_active Expired - Lifetime
- 1989-10-10 IL IL9193189A patent/IL91931A/en not_active IP Right Cessation
- 1989-10-10 NZ NZ230965A patent/NZ230965A/en unknown
- 1989-10-10 CA CA002000336A patent/CA2000336C/en not_active Expired - Fee Related
-
1991
- 1991-04-10 FI FI911722A patent/FI95201C/fi not_active IP Right Cessation
- 1991-04-10 DK DK91642A patent/DK64291D0/da not_active Application Discontinuation
- 1991-04-10 NO NO911395A patent/NO301522B1/no not_active IP Right Cessation
-
1993
- 1993-03-22 GR GR930400612T patent/GR3007420T3/el unknown
- 1993-11-30 JP JP5323298A patent/JPH0796034A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO301522B1 (no) | Fremgangsmåte for fremstilling av farmasöytisk preparat omfattende kalsitonin for intranasal tilförsel | |
| US4788221A (en) | Pharmaceutical compositions comprising calcitonin and an absorption-promoting substance | |
| EP1553953B1 (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
| US5801161A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| EP0296620A2 (en) | Use of N-acetylneuraminic-acid salts for the preparation of a medicament for decongesting nasal mucous membranes | |
| BG60934B2 (bg) | Терапевтични състави,съдържащи антрациклинови глюкозиди | |
| DE69932860T2 (de) | Verwendung von l-carnitin und seinen alkanoyl-derivaten als osmotisches mittel in lösungen für medizinische verwendung | |
| US6774137B2 (en) | Ophthalmic composition | |
| WO2010126818A1 (en) | Intranasal delivery system for dantrolene | |
| NO171723B (no) | Fremgangsmaate for fremstilling av pentamidinsalter, nyttige i behandling av profylakse av pneumocystis carinii pneumonia | |
| EP1283043B1 (en) | Ophthalmic solution | |
| US5514365A (en) | Pharmaceutical compositions comprising calcitonin for intranasal administration | |
| EP0345926A1 (en) | Pharmaceutical compositions containing pentamidine | |
| JP2012532852A (ja) | ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物 | |
| US4313952A (en) | Method of treating acute alcoholic intoxication with pyridoxine P.C.A. | |
| JP7340722B2 (ja) | コバラミン化合物の経鼻投与のための医薬組成物 | |
| EP0292100B1 (en) | Composition for the prophylaxis or treatment of pneumocystis carinii pneumonia | |
| US5955456A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| US4259353A (en) | Infusion solutions for the treatment of hepatic encephalopathy and method of using them | |
| JP2003073303A (ja) | 眼局所用液剤の清涼化作用の持続方法 | |
| Agen et al. | Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529 | |
| KR0156929B1 (ko) | 안정화된수용성펜타미딘염수용액 | |
| RU2662099C1 (ru) | Фармацевтические композиции для ингаляций, содержащие нитропростон | |
| EP0931548A2 (en) | Antifibrotic agent | |
| EP0417930A1 (en) | Low-irritative nasal preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |